We further analyzed patient heterogeneity and the effects of GDC0941 on the PI3K-Akt-mTOR profile for individual patients in the presence of insulin by comparing primary human AML cells incubated with insulin alone and those incubated with insulin plus GDC0941 (Fig. 4 left, Fig. 5). This evidence concerns the gene MTOR and acute myeloid leukemia.